Rainov N G, Kramm C M
Dept. Neurological Science, University of Liverpool, Clinical Sciences Centre, Lower Lane, Liverpool L9 7LJ, United Kingdom.
Curr Gene Ther. 2001 Nov;1(4):367-83. doi: 10.2174/1566523013348445.
Efficient virus and non-virus vector systems for gene transfer to tumor cells have been developed and tested in cell culture and in animal experiments. With some of the earliest and most comprehensively evaluated vectors, such as retroviruses, advanced clinical trials were performed in tumor patients. Malignant primary brain tumors (gliomas) have been chosen for the first clinical studies on novel gene therapy approaches because these tumors are non-metastatic and develop on the largely postmitotic background of normal glial and neuronal tissue. However, the human cancer gene therapy studies performed so far were not as successful as preclinical animal experiments. Furthermore, the clinical studies did not address major limiting factors for in vivo gene therapy, such as insufficient gene transfer rates to the tumor with the used local delivery modalities, and the resulting inability of a particular transgene-prodrug system to confer permanently eradicating cytotoxicity to the whole neoplasm. Critical evaluation of gene transfer and therapy studies has led to the conclusion that, even using identical vectors, the anatomical route of vector administration can dramatically affect both the efficiency of tumor transduction and its spatial distribution, as well as the extent of intratumoral and intracerebral transgene expression. This review concentrates on different physical methods for vector delivery to malignant primary brain tumors in experimental or clinical settings: stereotactic or direct intratumoral injection or convection-enhanced bulk-flow interstitial delivery; intrathecal and intraventricular injection; and intravascular infusion with or without modification of the blood-tumor-barrier. The advantages and drawbacks of the different modes and delivery routes of in vivo vector application, and the possibilities for tumor targeting by modifications of the native tropism of virus vectors or by using tissue-specific or inducible transgene expression are summarized.
用于将基因导入肿瘤细胞的高效病毒和非病毒载体系统已在细胞培养和动物实验中得到开发和测试。使用一些最早且评估最全面的载体,如逆转录病毒,在肿瘤患者中进行了先进的临床试验。恶性原发性脑肿瘤(胶质瘤)被选用于新型基因治疗方法的首批临床研究,因为这些肿瘤不发生转移,且在正常神经胶质和神经元组织的大部分有丝分裂后背景下发展。然而,迄今为止进行的人类癌症基因治疗研究并不像临床前动物实验那样成功。此外,临床研究未解决体内基因治疗的主要限制因素,例如使用的局部递送方式对肿瘤的基因转移率不足,以及特定转基因 - 前药系统无法对整个肿瘤赋予永久性根除细胞毒性。对基因转移和治疗研究的批判性评估得出结论,即使使用相同的载体,载体给药的解剖途径也会显著影响肿瘤转导的效率及其空间分布,以及肿瘤内和脑内转基因表达的程度。本综述集中于在实验或临床环境中向恶性原发性脑肿瘤递送载体的不同物理方法:立体定向或直接瘤内注射或对流增强的大量流间质递送;鞘内和脑室内注射;以及有或没有血脑肿瘤屏障修饰的血管内输注。总结了体内载体应用的不同模式和递送途径的优缺点,以及通过修饰病毒载体的天然嗜性或使用组织特异性或诱导性转基因表达实现肿瘤靶向的可能性。